Krystal Biotech earnings outlook and chart levels, shares on Nasdaq watched by biotech investors
25.06.2026 - 16:00:35 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 16:00.
Krystal Biotech Inc (US5012681064) remains a closely watched rare-disease gene therapy name on the Nasdaq. The companys shares trade in a historically volatile biotech pattern, with investors focusing on revenue trends and upcoming earnings per recent market commentary. Nasdaq trading data for KRYS
What recent reports say
Krystal Biotech reported its most recent quarterly results in May 2026, detailing year-on-year revenue growth from its gene therapy launch according to its investor materials. Analysts noted that commercialization expenses and pipeline investments continue to weigh on near-term profitability in this phase of the rollout. Krystal Biotech earnings and news releases
Recent coverage from biotech-focused research desks points to a combination of growing sales for the companys lead therapy and ongoing cash burn that is typical for gene therapy players. Commentators compare Krystal Biotech with other rare-disease and gene therapy names such as BioMarin and Sarepta when discussing valuation ranges and clinical execution risk.
Chart picture and technical levels
On the chart, Krystal Biotech shares have historically shown wide trading ranges on the Nasdaq, reflecting both clinical trial headlines and earnings updates over recent years. Technical analysts frequently refer to moving averages and prior swing highs to assess momentum in KRYS as liquidity can be thinner than in larger S&P 500 constituents. KRYS chart and technical overview
Daily trading volumes in Krystal Biotech fluctuate around news dates, while option activity occasionally signals hedging or speculative positioning in advance of results. Short interest data, as published by exchange statistics, show that a portion of the free float is borrowed, a pattern not unusual for clinical-stage and early-commercialization biotech stocks.
All news and analysis on the Krystal Biotech shares
Further background on Krystal Biotech, including ad-hoc releases and historical coverage, can be found in the dedicated topic area and on the companys investor relations pages.
The product behind the stock
Krystal Biotech generates revenue primarily from its gene therapy Vyjuvek, approved for the treatment of dystrophic epidermolysis bullosa, a rare skin disease. The company is also advancing a pipeline of additional dermatology and respiratory gene therapies that could expand its addressable market over time.
The listing in brief
Krystal Biotech shares are listed on the Nasdaq under the ticker KRYS, with trading and pricing in US dollars based on the latest available exchange data.
Krystal Biotech at a glance
- Company: Krystal Biotech Inc
- ISIN: US5012681064
- WKN: A2N6KP
- Ticker: KRYS
- Trading venue: Nasdaq
- Price (as of 2026-06-25, 15:55): 175.00 USD
- Market cap: 4.5 billion USD (as of 2026-06-25)
- Sector / industry: Health Care - Biotechnology
- Index membership: not a member of a major headline index such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
